Corline Biomedical
12.55 SEK 0%Be the first to follow this company
Corline Biomedical operates in the pharmaceutical industry. The company develops with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The drug candidates are based on the same basic technology as the medical technology products. Corline Biomedical operates on the Nordic market and is headquartered in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CLBIO
Daily low / high price
12.55 / 12.55
SEK
Market cap
269.71M SEK
Turnover
4.39K SEK
Volume
350
Financial calendar
Interim report
2024-08-23
Interim report
2024-11-07
Annual report
2025-02-17
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Adam Dahlberg | 26.7 % | 26.7 % |
HealthInvest Microcap Fund AB | 9.4 % | 9.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Kardium visar positiva resultat i 1-årsuppföljningen av PULSE-EU
Kommuniké från årsstämma i Corline Biomedical AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools